Kidney and Urinary Tract Infections DRG 690 Reimbursement

Summary & Overview

Kidney and Urinary Tract Infections without MCC: Inpatient Reimbursement Overview

DRG 690 encompasses inpatient admissions for kidney and urinary tract infections without a Major Complication or Comorbidity, focusing on cases like pyelonephritis and uncomplicated complicated urinary tract infections. It matters for inpatient reimbursement because assignment to this Diagnosis-Related Group determines Medicare payment weight based on clinical severity and expected resource use.

DRG Kidney and Urinary Tract Infections without MCCDRG 690Diagnosis-Related GroupInpatient ReimbursementMedicareUrologyInfectious DiseaseHospital MedicineUrinary Tract InfectionPyelonephritis

DRG 690 Overview

DRG 690 covers hospital admissions for kidney and urinary tract infections without a Major Complication or Comorbidity. It includes primary diagnoses such as pyelonephritis and complicated urinary tract infections when no higher-severity comorbid conditions are present. This Diagnosis-Related Group is used to assign inpatient payments under the Medicare prospective payment system and influences resource intensity and reimbursement. Understanding its clinical scope helps clarify case-mix and payment expectations for affected hospitalizations.

National Payment Rates

Across commercial payers the observed rate range runs from about $7.3K (BCBS median) up to $14K (Aetna mean), with payer medians and means clustering between roughly $7K and $15K. The widest spread between payer percentiles appears in Anthem (min $390 to max $29K) as shown in the table and chart below. Refer to the table and chart below for payer-specific percentiles and distribution detail.

Mean Rates by Payer — National — DRG 690

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska commercial rates for DRG 690 span roughly $13K to $20K across major payers, with Cigna at the top end (mean $20K) and Blue Cross Blue Shield and Anthem clustering at the lower end (mean $13K). This state distribution sits noticeably above the national BCBS mean and median, representing a meaningful upward deviation from those national averages. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $20K); Lowest payer: BCBS / Anthem (mean $13K).
Alaska’s rates range from $13K to $20K across major commercial payers, notably higher than national BCBS mean (~$7.3K) and closer to national Anthem/Cigna averages, indicating a meaningful upward deviation from some national benchmarks.

Clinical Trials

Acute antimicrobial strategy trials: randomized studies comparing short-course versus standard-duration antibiotic regimens or route-of-administration strategies (intravenous-to-oral switch protocols) for hospitalized patients with complicated urinary tract infections and pyelonephritis. These trials enroll adults admitted with confirmed kidney or upper urinary tract infections without major comorbid complications, focusing on time to clinical resolution, readmission rates, length of stay, and antibiotic-related adverse events. Results inform clinicians about safe de-escalation and stewardship practices and help payers evaluate cost-effective inpatient antibiotic use and opportunities to shorten hospital stays.
Diagnostic and risk-stratification studies: prospective cohort or diagnostic accuracy studies evaluating biomarkers, clinical prediction rules, and imaging criteria to distinguish patients who require inpatient care from those safe for outpatient management. These studies target diverse inpatients and emergency-department–presenting adults with suspected kidney or urinary tract infections, assessing predictors of progression to sepsis, need for invasive procedures, or treatment failure. Better risk stratification reduces unnecessary admissions and resource use, guiding authorization policies and care pathways used by providers and payers to allocate inpatient resources appropriately.
Post-discharge outcomes and care-transition research: observational or interventional studies assessing readmission prevention bundles, outpatient follow-up timing, and patient education or telehealth interventions after discharge for kidney and urinary tract infections. These trials enroll patients recently discharged under this DRG to measure 30-day readmissions, recurrent infection rates, outpatient antibiotic adherence, and downstream costs. Findings are relevant for hospitals and payers aiming to lower readmissions, optimize transitional care protocols, and align reimbursement incentives with improved long-term outcomes.

Related Codes

672-URETHRAL-PROCEDURES-WITHOUT-CC-MCC

Urethral Procedures without CC/MCC: Inpatient Reimbursement Overview

698-OTHER-KIDNEY-AND-URINARY-TRACT-DIAGNOSES-WITH-MCC

Other Kidney and Urinary Tract Diagnoses with MCC: Inpatient Reimbursement Overview

695-KIDNEY-AND-URINARY-TRACT-SIGNS-AND-SYMPTOMS-WITH-MCC

Kidney and Urinary Tract Signs and Symptoms with MCC: Inpatient Reimbursement Overview

659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

671-URETHRAL-PROCEDURES-WITH-CC-MCC

Urethral Procedures with CC/MCC: Inpatient Reimbursement Overview

694-URINARY-STONES-WITHOUT-MCC

Urinary Stones without MCC: Inpatient Reimbursement Overview

700-OTHER-KIDNEY-AND-URINARY-TRACT-DIAGNOSES-WITHOUT-CC-MCC

Other Kidney and Urinary Tract Diagnoses without CC/MCC: Inpatient Reimbursement Overview

687-KIDNEY-AND-URINARY-TRACT-NEOPLASMS-WITH-CC

Kidney and Urinary Tract Neoplasms with CC: Inpatient Reimbursement Overview

683-RENAL-FAILURE-WITH-CC

Renal Failure with CC: Inpatient Reimbursement Overview

670-TRANSURETHRAL-PROCEDURES-WITHOUT-CC-MCC

Transurethral Procedures without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 41

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$7.5K	$35K	$5.7K	91K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 690

Key Insights for Alaska

Highest payer: Cigna (mean $20K); Lowest payer: BCBS / Anthem (mean $13K).
Alaska’s rates range from $13K to $20K across major commercial payers, notably higher than national BCBS mean (~$7.3K) and closer to national Anthem/Cigna averages, indicating a meaningful upward deviation from some national benchmarks.

Clinical Trials

Acute antimicrobial strategy trials: randomized studies comparing short-course versus standard-duration antibiotic regimens or route-of-administration strategies (intravenous-to-oral switch protocols) for hospitalized patients with complicated urinary tract infections and pyelonephritis. These trials enroll adults admitted with confirmed kidney or upper urinary tract infections without major comorbid complications, focusing on time to clinical resolution, readmission rates, length of stay, and antibiotic-related adverse events. Results inform clinicians about safe de-escalation and stewardship practices and help payers evaluate cost-effective inpatient antibiotic use and opportunities to shorten hospital stays.
Diagnostic and risk-stratification studies: prospective cohort or diagnostic accuracy studies evaluating biomarkers, clinical prediction rules, and imaging criteria to distinguish patients who require inpatient care from those safe for outpatient management. These studies target diverse inpatients and emergency-department–presenting adults with suspected kidney or urinary tract infections, assessing predictors of progression to sepsis, need for invasive procedures, or treatment failure. Better risk stratification reduces unnecessary admissions and resource use, guiding authorization policies and care pathways used by providers and payers to allocate inpatient resources appropriately.
Post-discharge outcomes and care-transition research: observational or interventional studies assessing readmission prevention bundles, outpatient follow-up timing, and patient education or telehealth interventions after discharge for kidney and urinary tract infections. These trials enroll patients recently discharged under this DRG to measure 30-day readmissions, recurrent infection rates, outpatient antibiotic adherence, and downstream costs. Findings are relevant for hospitals and payers aiming to lower readmissions, optimize transitional care protocols, and align reimbursement incentives with improved long-term outcomes.